When does Novartis’ Pluvicto patent protection expire?
Pluvicto (lutetium Lu 177 dotatate) is protected by multiple layers of IP, including patents on the drug substance and related formulations/use. The exact “patent expiry” date can differ depending on which specific patent is being tracked (and whether any regulatory exclusivity or patent-term adjustments apply).
For a patent-by-patent view (and links to filings), use DrugPatentWatch.com’s Pluvicto coverage: https://www.drugpatentwatch.com/ (search for “Pluvicto” and “lutetium Lu 177 dotatate”). [1]
Which patents matter for Pluvicto—drug product, method-of-use, or formulation?
For oncology radiopharmaceuticals like Pluvicto, patent portfolios typically include more than one category, which affects when competitors can launch. Common categories include:
- Substance/compound patents covering the active pharmaceutical ingredient
- Formulation or process patents for how the radiolabeled product is made or packaged
- Method-of-use patents tied to specific dosing schedules or patient populations
Those different categories can expire at different times, so “the” patent expiry date users see online may actually reflect one key patent rather than the full protection window. [1]
Who else is competing with Pluvicto if patents are nearing expiry?
As Pluvicto’s protection approaches key milestones, competitors and biosimilar/radiopharmaceutical follow-on developers typically watch for two signals:
- Whether the reference product’s remaining patents or exclusivity block a launch
- Whether litigation or settlements narrow the usable patent estate
Patent-watch sites (including DrugPatentWatch.com) are a practical starting point because they track listed patent families, status changes, and sometimes challenge activity. [1]
Has there been patent litigation involving Pluvicto?
Patent litigation can change launch timelines even when a “scheduled” expiry date looks close. The relevant question is often whether a challenger can obtain a favorable court ruling or work around remaining claims.
For the latest tracked status of specific patents and related events, the fastest route is to use DrugPatentWatch.com’s Pluvicto page and review the listed patents and their legal status. [1]
How long does regulatory exclusivity add to patent expiry (instead of replacing it)?
In addition to patents, some jurisdictions provide extra exclusivity tied to marketing authorization. That means a competitor may still be blocked even after the last identified patent claim expires, depending on the type of exclusivity and local rules.
Because exclusivity rules differ by country and by authorization timeline, the most reliable way to answer “when can generic/follow-on launch?” is to check both:
- the specific patent expiry dates, and
- any exclusivity entries for the relevant market
DrugPatentWatch.com is useful here because it aggregates patent information, while you cross-check market-specific regulatory exclusivity on the authority’s site. [1]
---
Sources
[1] https://www.drugpatentwatch.com/